ORIC Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ORIC Pharmaceuticals (ORIC).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

17Buy

Consensus RatingBuy# Analysts17Avg. Consensus PT$20Upside to Avg. PT+125.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$26
Oct 27, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$17→$14
Oct 26, 2026	Stifel	Laura Prendergast	PT Raise	Buy	$14→$18
Oct 14, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$23→$26
Oct 5, 2026	Leerink Partners	Asthika Goonewardene	Initiate	Outperform	$26
Sep 23, 2026	BTIG	Jeet Mukherjee	Initiate	Buy	$26
Aug 10, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$25→$27
Jun 8, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$25
May 15, 2026	Goldman Sachs	Corinne Johnson	Upgrade	Buy	$15
May 5, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$17→$16
Apr 2, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$25
Apr 1, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$20→$17
Mar 13, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$25
Feb 24, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$16→$17
Feb 24, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$23→$25
Feb 24, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$20
Jan 13, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$20
Jan 7, 2026	Piper Sandler	Kelsey Goodwin	Initiate	Overweight	$22
Dec 8, 2025	Wells Fargo	Derek Archila	PT Raise	Overweight	$19→$25
Dec 8, 2025	Wedbush	David Nierengarten	Maintained	Outperform	$20

Analyst Ratings News

PRO
BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target

BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14

Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18

Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.

Benzinga Newsdesk

Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for ACI, ORIC, JPM, SHOP, META and U; KTB upgraded to Buy. Domino’s target was cut.

Avi Kapoor

PRO
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and raises the price target from $23 to $26.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

Leerink Partners analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform rating and announces Price Target of $26.

Benzinga Newsdesk

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target

PRO
Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14

PRO
Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18

Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

PRO
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

People Also Watch

People Also Watch

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target

PROWedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14

PROStifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18

Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday

PROJP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

PROLeerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target

PRO
Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14

PRO
Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18

PRO
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

PRO
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26